Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms
Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, have been identified in several neoplastic diseases. Rearranged ALK is a driver of tumorigenesis, which activates various signaling pathway associated with proliferation and survival. To date, several agents that...
Збережено в:
Автори: | , , |
---|---|
Формат: | Книга |
Опубліковано: |
Frontiers Media S.A.,
2023-10-01T00:00:00Z.
|
Предмети: | |
Онлайн доступ: | Connect to this object online. |
Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Інтернет
Connect to this object online.3rd Floor Main Library
Шифр: |
A1234.567 |
---|---|
Примірник 1 | Доступно |